Immune checkpoint inhibitors (ICIs) have shown significant promise in treating tumors. Immune checkpoint inhibitors are a form of immunotherapy, which redi | Immunology ...

A deep learning radiomic biomarker has been developed and validated to predict responses to immune checkpoint inhibitors in ...

New data suggests researchers may have found one of their most promising candidates yet for the next generation in ...

Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy.

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...

A recent study highlights an increased risk of thromboembolic events in metastatic lung cancer patients treated with immune ...

Immunotherapies have become a cornerstone in cancer treatment, with current therapies like checkpoint inhibitors enhancing ...

The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...

New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.

The global cancer immunotherapy market was valued at more than US$ 92.11 billion in 2024. It is anticipated to increase at a CAGR of 12.84% between 2024 and 2031. The worldwide cancer immunotherapy ...